Form 4: Teva Pharmaceuticals: Director Sol J. Barer Trades Shares

Teva Pharmaceuticals Director Sol J. Barer reported a transaction involving ordinary shares and restricted share units on June 5, 2026.

Summary

• Sol J. Barer, a Director at Teva Pharmaceuticals Industries Ltd., reported a transaction on June 5, 2026.
• The transaction involved the acquisition of 21,739 ordinary shares.
• These shares were acquired through the vesting of restricted share units.
• The restricted share units were granted on June 5, 2025, and vested on June 5, 2026.
• Following this transaction, Mr. Barer beneficially owns 448,011 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine share vesting transaction by a director rather than a discretionary trade.

Positives

• Director Sol J. Barer's beneficial ownership of Teva Pharmaceuticals ordinary shares increased by 21,739.
• The acquisition of shares through vesting of restricted share units indicates a fulfillment of prior compensation awards.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and reflect normal compensation vesting schedules for executives and directors within the pharmaceutical industry.

Stakeholder Impact

• Shareholders: The transaction reflects a standard compensation event for a director and does not inherently signal a change in the director's investment strategy or confidence in the company.

Key Dates

Keywords

Teva Pharmaceuticals, Form 4, SEC Filing, Insider Trading, Director Transaction, Share Vesting, TEVA, Beneficial Ownership